ImmunityBio FDA Warning Sends Shares Down 20%
ImmunityBio FDA warning over Anktiva promotions spurred investor concern and a sharp drop, concentrating near-term market and legal risk for shareholders.
KEY TAKEAWAYS
- FDA warning alleged misleading Anktiva promotions and omissions of required risk information.
- Shares fell 20% following the warning, prompting investor concern and law-firm investigations.
- Company must submit corrective plan and communications within 15 working days.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
ImmunityBio (IBRX) shares fell after the FDA issued a warning letter on or before March 24, 2026 (ET), accusing the company of making misleading claims about its cancer therapy Anktiva (nogapendekin alfa inbakicept-pmln). The regulatory action escalated scrutiny, spurred investor concern, and prompted law-firm investigations.
FDA Warning and Regulatory Details
The FDA's warning letter cited a television advertisement and a podcast that overstated Anktiva’s uses and effectiveness. The materials, featuring Chief Executive Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong, suggested the drug could treat a broad range of cancers, prevent cancer in people exposed to radiation, and work as a single injection. The agency said these claims omitted required risk information and material facts about the drug’s approved indication. The podcast had not been submitted for FDA review before publication, violating federal rules.
The letter referenced federal regulations on fair balance in promotional materials (21 CFR 202.1(e)(6)(i)) and the requirement to submit promotional content for review (21 CFR 314.81(b)(3)). It directed ImmunityBio to submit a corrective plan and communications to affected audiences within 15 working days.
This warning is the third FDA action on similar promotional issues involving ImmunityBio or its subsidiary Altor BioScience, following untitled letters in September 2025 and January 2026.
Anktiva is approved only for adult patients with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. It is administered intravesically alongside BCG therapy.
Market Reaction and Legal Risks
Shares dropped sharply after the FDA warning, reflecting investor concern over the regulatory escalation. The warning also triggered law-firm investigations into potential claims involving company executives, concentrating near-term legal and market risks for shareholders. The combination of heightened regulatory scrutiny and outside legal inquiries has increased uncertainty around the company’s communications and compliance.
